ReviewThe European journal of neuroscience2025
Gut Microbiota Composition and Modulation in Developmental and Epileptic Encephalopathies.
Review in The European journal of neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut-Brain Axis Modulation by Short-Chain Fatty Acids Exerts Disease-Modifying Effects in a Murine Model of Drug-Resistant Epilepsy.Annals of neurology · 2026Article
- Intestinal microbial community assessment in patients with different forms of epilepsy and autoimmune encephalitis: An exploratory study.Gut microbes reports · 2026Article
- Gut Microbiota Composition and Modulation in Developmental and Epileptic Encephalopathies.The European journal of neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota (GM) is a rapidly evolving field of research that is increasingly explored in the context of various diseases. The complex interactions between the host and microbial communities play a crucial role in health and well-being. It is now understood that the GM communicates with nearly every human organ, including the central nervous system (CNS), through the microbiome-gut-brain (MGB) axis. Furthermore, accumulating evidence suggests that pathological shifts in the GM may lead to various neurological disorders, including epilepsy. While the link between epilepsy and the MGB axis is increasingly recognized, studies investigating the impact of GM alterations in developmental and epileptic encephalopathies (DEEs) remain limited. This review highlights recent clinical and preclinical studies examining the impact of GM composition on DEEs, with a focus on infantile epileptic spasms syndrome (IESS) and Dravet syndrome (DS). Further investigation into the relationship between GM dysbiosis and the progression of DEEs is crucial for developing potential therapeutic strategies aimed at modulating the GM to alleviate seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.